Findings
stroke
STROKE
In this prespecified subgroup analysis of the CHANCE-2 trial, new stroke occurred less often with ticagrelor-aspirin vs clopidogrel-aspirin, irrespective of metabolizer status: 6.0% vs 7.6%, respectively, among patients with intermediate metabolizer status and 5.7% vs 7.5%, respectively, among poor metabolizers. No difference was found in treatment effect between poor and intermediate 